Nona Biosciences announced a strategic collaboration with OverT Bio to develop next-generation cell therapies for solid tumors October 15, 2024
First Patient Dosed in Ph 1/2 Trial of PFL-241/STX-241 in Locally Advanced or Metastatic NSCLC patients October 15, 2024
FAILED TRIAL: Ph 2 study of TG4001 + avelumab vs avelumab in patients with R/M HPV16-positive cervical and anogenital tumors did not meet the primary objective of PFS improvement October 15, 2024
FDA Clears IND Application for Ph 1/2 ADCElerate-01 Trial of ADCE-D01 Trial in Patients with Metastatic and/or Unresectable Soft Tissue Sarcoma (STS) October 15, 2024
FDA Approves Perioperative Treatment of Neoadjuvant Opdivo and Chemo Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable NSCLC October 15, 2024
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into 1L HCC Pivotal Trial October 15, 2024
Ph 3 SunRISe-2 trial in MIBC patients discontinued for not showing superiority versus chemoradiation October 15, 2024
KEYTRUDA Met Primary Endpoint of EFS as Perioperative Treatment Regimen in Patients With Resected, Locally Advanced SCCHN October 15, 2024
Type II variation application to the EMA for DARZALEX® (daratumumab) SC-based quadruplet regimen for newly diagnosed multiple myeloma patients October 15, 2024
FDA approves Itovebi for advanced HR+ve, HER2-neg breast cancer with a PIK3CA mutation October 15, 2024
Exelixis and Merck to Evaluate Zanzalintinib in Combination With KEYTRUDA in Head and Neck Cancer and in Combination With WELIREG in RCC October 15, 2024
Ono Enters into License Agreement for LCB97 to generate novel ADC candidates by leveraging ConjuAll™ ADC platform with LigaChem Biosciences October 15, 2024
MediLink Announces Global Clinical Trial Collaboration and Supply Agreement on YL201 Combination Therapy October 15, 2024
MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors October 15, 2024
Boehringer Ingelheim and Circle Pharma announce new research collaboration to develop a novel precision cancer treatment October 15, 2024
First patient enrolled in Ph 1/2a clinical trial for Lenti-HPV07 against oropharyngeal and cervical cancers October 15, 2024
BDTX-1535 program to be advanced into pivotal development based on robust Ph 2 clinical data from EGFRm NSCLC patients October 15, 2024
First Patient Dosed in Ph 2 Clinical Trial of Radspherin® in Ovarian Cancer Patients October 15, 2024
Interim data from Ph 1 clinical study of misetionamide (GP-2250) in combination with gemcitabine in patients with pancreatic adenocarcinoma announced October 15, 2024
Ph 1 results for Ribrecabtagene autoleucel (DRL-1801) from the SWASTH study in patients with R/R multiple myeloma announced October 15, 2024
